The OncLive Pediatric Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of cancers in pediatric patients, including acute lymphoblastic leukemia, acute myeloid leukemia, brain cancers, sarcomas, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in childhood and adolescent and young adult cancers.
October 29th 2024
The FDA has expanded the approval of methotrexate to include use in pediatric patients with acute lymphoblastic leukemia.
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Palliative Care Opportunities Missed in Pediatric Hematology/Oncology
Physicians are missing opportunities to refer pediatric patients with hematologic malignancies to palliative care at the end of life, and those who are admitted to palliative care tend to have very advanced disease.
Absolute Risk for Developing Most STS Low in Childhood Cancer Survivors
While survivors of childhood cancers are at increased risk for developing soft-tissue sarcomas compared with the general population, the absolute risk for developing STS is low except for leiomyosarcoma after retinoblastoma.
Dr. Young on the Challenges of Using Anticoagulants in Children With Cancer
November 28th 2017Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, discusses the challenges of using anticoagulants in children with cancer.
MRD, Genetic Classification Provide More Accurate Risk Stratification in Pediatric ALL
Investigators working in the UK and Europe found a correlation between minimal residual disease kinetics and risk for relapse in pediatric patients with acute lymphoblastic leukemia.
Dr. Daver on CAR T-Cell Therapy Approval in Pediatric ALL
November 16th 2017Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the approval of a chimeric antigen receptor (CAR) T-cell therapy in pediatric acute lymphoblastic leukemia.
No Benefit With Prolonged Native E. Coli Asparaginase in Pediatric ALL, NHL
Treatment with prolonged native E. coli asparaginase therapy for children with acute lymphoblastic leukemia or non-Hodgkin lymphoma not only failed to improve survival versus the standard regimen, but also resulted in an increase in infections and allergy.
Dr. Young on Other Options for Managing Bleeding in Children With Cancer
October 23rd 2017Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, USC, discusses other options for managing bleeding in children with cancer.
Dr. Young on Using Vitamin K Antagonists in Children With Cancer
October 19th 2017Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, USC, discusses using vitamin-K antagonists in children with cancer.
Dr. Young Discusses Using Anticoagulants in Children With Cancer
October 17th 2017Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, USC, discusses using anticoagulants in children with cancer.
Reinduction Regimen Effective in Late Marrow-Relapsed Pediatric ALL
In the CALL-0603 study of 44 patients with first marrow-relapsed childhood acute lymphoblastic leukemia, the second complete remission rate was 72.7% for a chemotherapy regimen that included a reduced dose of idarubicin.
Dr. Young Discusses Thromboembolic Events in Pediatric Cancer
September 21st 2017Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, USC, discusses the occurrence of thromboembolic events in pediatric cancer.